Ionis Pharmaceuticals, Inc. Payments of Debt Issuance Costs
Ionis Pharmaceuticals, Inc. (IONS) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-19
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for the quarter ending 2023-09-30 was $517.00K.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2023 was $14.18M.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ionis Pharmaceuticals, Inc. payments of debt issuance costs for fiscal 2021 was $15.61M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $517.00K derived: sum of 2 quarters · filed 2025-02-19 | $14.18M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $517.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $14.18M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $13.66M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $58.00K derived: sum of 2 quarters · filed 2023-02-22 | $15.61M 10-K · filed 2023-02-22 | |
| 2021-09-30 | -$26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $15.53M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $15.55M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $10.43M 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |